2017 / 02

Next Paper
DOI: 10.24075/brsmu.2017-02-08
Copyright: © 2017 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Effectiveness and safety of treatment with domestic cepeginterferon alpha-2b in patients with chronic hepatitis C infection. Actual clinical experience

Tkacheva SV1, Manapova ER1, Sozinova YuM1,2, Yakupova FM1,2, Fazylova YuV3
About authors

1 Department of Infectious Diseases, Faculty of Medical and Preventive Care,
Kazan State Medical University, Kazan, Russia

2 Diagnostic and Consultation Unit,
Agafonov Republican Clinical Hospital of Infectious Diseases, Kazan, Russia

3 Department of Dental Therapy, Faculty of Dentistry,
Kazan State Medical University, Kazan, Russia

Correspondence should be addressed: Svetlana Tkacheva
ul. Butlerova, d. 49, Kazan, Russia, 420012; ur.liam@umgk-avehcakt

About paper

All authors' contribution to this work is equal: selection and analysis of literature, planning of the manuscript's structure, data interpretation, drafting of the manuscript, editing.

Received: 2017-02-09 Accepted: 2017-03-10 Published online: 2017-06-02
|
  1. European Association for Study of Liver. Recommendations on Treatment of Hepatitis C 2015. J Hepatology. 2015 Jul; 63 (1): 199–236. DOI: 10.1016/j.hep.2015.03.025.
  2. Rekomendatsii po diagnostike i lecheniyu vzroslykh bol’nykh gepatitom C (Letter of the Ministry of Health of the Russian Federation No. 17-00-6444 from 03.09.2014). Moscow, 2014. 91 p. Russian.
  3. Enaleeva DSh, Fazylov VKh, Sozinov AS. Khronicheskie virusnye gepatity В, С i D: rukovodstvo dlya vrachey. Moscow: GEOTAR- Media; 2015. 192 p. Russian.
  4. Pavlov AI, Kirillov SM, Ponomarenko DS, Havanshanov AK, Fadina JV, Bobkova IV, et al. [Efficacy and safety of сepeginterferon alfa- 2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice]. Journal Infectology. 2016; 8 (3): 92–8. DOI: 10.22625/2072-6732-2016- 8-3-92-98. Russian.
  5. Mayevskaya MV, Znoyko OO, Klimova EA, Maximov AS, Kizhlo SN, Petrochenkova NA, et al. [Efficacy of pegylated interferon alfa- 2b «Algeron» in the treatment of chronic hepatitis C]. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013; 23 (1): 30–6. Russian.
  6. Mayevskaya MV, Znoyko OO, Klimova EA, Maximov AS, Kizhlo SN, Petrochenkova NA, et al. [Treatment of chronic hepatitis C by cepeginterferon alpha-2b in combination to ribavirin (Final results of randomized comparative clinical study)]. The Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014; 24 (2): 53–64. Russian.
  7. Blokhina NP, Nurmuhametova EA, Rusanova MG, Gagarina IV, Mar’jamova ES, Kuznetsova NA, et al. [The efficacy and safety of double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alfa 2b and ribavirin) treatment regimens in chronic hepatitis C patients. The experience of everyday clinical practice]. Journal Infectology. 2016; 8 (2): 48–55. Russian.
  8. Znoyko O, Mayevskaya MV, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Rapid and early virologic response to сepeginterferon-alfa-2b in combination with ribavirine in treatment-naïve patients with chronic HCV. Hepatology. 2012; 56 (4 Suppl 1): 586A.
  9. Znoyko O, Maevskaya M, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Early virologic response (EVR) in treatment-naive mono-infected chronic hepatitis C (CHC) patients treated with cepeginterferon-alfa-2b (cePEG-IFNa-2b) plus ribavirin. J Hepatology. 2013; 58 (Suppl 1): S348–9.
  10. Znoyko O, Maevskaya M, Klimova E, Kizhlo S, Petrochenkova N, Maximov S, et al. Сepeginterferon-alfa-2b combination with ribavirin in treatment-naive patients with chronic hepatitis С. J Hepatology. 2014; 60 (Suppl 1): S476.
  11. Znoyko OO, Linkova YuN, Morozova MA. Klinicheskiy opyt primeneniya skhemy troynoy terapii, vklyuchayushchey tsepeginterferon al'fa-2 b, simeprevir i ribavirin, u patsientov s khronicheskim gepatitom C genotipa 1. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2016; (2): 100–9. Russian.